CRL vs SHC
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. SHC: A global provider of essential sterilization and lab testing services for the healthcare industry.
Side-by-side fundamentals
| Metric | CRL | SHC | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $298.00 | $17.83 | |
| Market cap | $14.2B | $5.1B | |
| P/E as of 2026-10-08 | n/a | 43.46 | |
| Net margin FY2025, SEC XBRL | -3.6% | +6.7% | SHC higher |
| Gross margin FY2025, SEC XBRL | n/a | +55.5% | |
| Operating margin | +0.6% | +27.0% | SHC higher |
| ROE FY2025, SEC XBRL | -4.6% | +12.9% | SHC higher |
| ROA FY2025, SEC XBRL | -2.0% | +2.4% | SHC higher |
| Debt / equity as of 2026-09-03 | 0.93 | 3.59 | CRL lower |
| Revenue growth (YoY) as of 2026-09-03 | -0.7% | +7.4% | SHC higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | +5.1% | SHC higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.37 | 1.14 | |
| 1-year return as of 2026-10-08 close | +71.8% | +11.4% | CRL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.